Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-6 dendritic cell immunotherapy after neoadjuvant FOLFIRINOX for borderline resectable pancreatic cancer
NL-OMON61117Phase 3Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of MesoPher in pancreatic cancer (PC), sponsored by Erasmus MC. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
MesoPher
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON61117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61117.